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1. Introduction
  Despite valuable progress achieved by the recently 
established global eradication program, malaria still 
remains a major cause of morbidity and mortality, with 
300-500 million clinical cases and almost one million 
deaths occurring each year[1]. In severe malaria, besides 
primary therapy including quinine and artesunate, which 
are effective against the parasite, in the recent years several 
new adjunctive therapies have undergone trials. The aim 
was to reduce malaria-induced pathophysiology, to reduce 
clinical symptoms and increase survival. However, results 
have been disappointing, with albumin being so far the only 
adjunctive therapy associated with reduced mortality in 
children with severe malaria[2]. Thus, a better understanding 
of mechanisms underlying the pathophysiology of 
complicated malaria in order to define new affordable 
treatment appears quite urgent. 
  In this context, convincing evidence on the involvement 
of human matrix metalloproteinases (MMPs) in malaria 
pathogenesis emerged very recently, thereby offering a new 
kaleidoscope of potential targets for adjunctive therapy[3-6]. 
MMPs are proteolytic enzymes able to disrupt subendothelial 
basement membrane and tight junctions and to modulate 
the activity of several pro-inflammatory mediators[7]. All 
these functions could be particularly crucial in facilitating 
CM development. In vivo, enhanced levels of MMP-1 in the 
brain[8], of MMP-9 in the whole blood[9], and of MMP-8 in 
the plasma[10] of human patients with severe malaria were 
described, whereas increased mRNA or protein levels of 
MMP-2, MMP-7 and MMP-9 were found in the brain of 
mice with CM[11,12]. In vitro, P. falciparum-infected red 
blood cells (RBCs) and malarial pigment haemozoin (HZ), 
a parasite waste product of haemoglobin digestion, have 
been shown to alter MMP production by phagocytic cells: 
in human monocytes, the phagocytosis of parasitized RBCs 
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or of HZ has been reported to enhance the expression and 
activity of MMP-9[13-17]; in HZ-fed murine macrophages, 
altered balances between MMP-9 and its endogenous 
inhibitor [tissue inhibitor of metalloproteinase-1 (TIMP-1)] 
were shown[18]. 
  In addition to phagocytes, another primary source of 
MMPs is represented by the endothelium[19,20]. To date, 
however, not many data on malaria-dependent regulation 
of endothelial MMPs are available. Two recent papers from 
our group demonstrated that HZ can upregulate MMP-9 
production by human endothelial cells obtained from either 
small[21] or large[3] vessels. In the present study, we extended 
the previous observations by investigating the regulation 
of MMP-1, -2, -3, -9 and TIMP-1 in human microvascular 
endothelium after exposure to whole erythrocytes infected 
by two different strains of P. falciparum.
 
2. Materials and methods
2.1. Materials
  All materials were from Sigma Italia, Milan, Italy, unless 
otherwise stated. MCDB 131 and RPMI 1640 medium were 
from GIBCO BRL, Paisley, Scotland; foetal calf serum was 
from HyClone, South Logan, UT; epidermal growth factor was 
from PeproTech EC, London, UK; Hepes buffer, Glutammine 
and Penicillin/Streptomycin were from EuroClone, Pero, 
Italy; monoclonal anti-human MMP-1, MMP-3, MMP-9, 
TIMP-1 Abs were from Santa Cruz Biotechnology, 
Heidelberg, Germany; computerized densitometer Chemidoc 
was from Biorad, Segrate, Italy.
2.2. Endothelial cell cultures
  A long-term cell line of dermal microvascular endothelial 
cells (HMEC-1) immortalized by SV 40 large T antigen[22] 
was kindly provided by the Center for Disease Control, 
Atlanta, GA. Cells were maintained in MCDB 131 medium 
supplemented with 10% foetal calf serum, 10 ng/mL of 
epidermal growth factor, 1 g/mL of hydrocortisone, 2 mM
glutamine, 100 units/mL of penicillin, 100 g/mL of 
streptomycin and 20 mM Hepes buffer, pH 7.4. 
2.3. P. falciparum cultures
  P. falciparum parasites (D10 and W2 strains; mycoplasma 
free) were kept in culture as described (21) at 5% hematocrit 
(human type A+ RBCs) at 37 ℃ in RPMI 1640 medium 
supplemented with 10% heat-inactivated A+ human plasma, 
20 mM Hepes buffer, pH 7.4, in a standard gas mixture 
consisting of 1% O2, 5% CO2, 94% N2. 
2.4. Isolation of trophozoite-stage parasitized RBCs
  Parasite cultures (2%-4% parasitemia) were washed twice 
with serum-free culture medium, resuspended to 25% 
haematocrit and fractionated on a discontinuous Percoll/4% 
sorbitol (wt/vol) gradient (0%, 40%, 60%, 70%, 80%)[23]. After 
centrifugation at 1 075 g, trophozoite-stage parasitized RBCs 
were collected at 40%-60% gradient interphase, and washed 
three times with PBS.
2.5. HMEC-1 treatment
  HMEC-1 were seeded at 105 cells/well in 24 well flat bottom 
tissue culture clusters. After overnight incubation to allow 
cell adhesion, monolayers were exposed to trophozoite-stage 
infected RBCs (2% final haematocrit, 5%-10% parasitemia) 
in a humidified CO2/air-incubator at 37 曟 for 72 h. In some 
experiments, cells were co-incubated with pRBC for 3 h, 
washed and replaced with medium for 72 h. All experiments 
were performed in serum-free medium. At the end of each 
treatment, supernatants were collected and used for MMPs 
assays.
2.6. Assay of proMMP-2/MMP-2 and proMMP-9/MMP-9 
levels by SDS-PAGE gelatin zymography
  The levels of MMP-2 and MMP-9 and their pro-forms were 
evaluated by SDS-PAGE gelatin zymography in the cell 
supernatants, as previously described[21]. Briefly, 15 毺L
of supernatants were loaded on 8% polyacrylamide gels 
containing 0.1% gelatin under non-denaturing and non-
reducing conditions. Following electrophoresis, gels were 
washed with Triton TX-100 2,5% and incubated for 18 h 
at 37 曟 in a collagenase buffer. After washings, bands 
were visualized by Comassie Brilliant Blue R-250 staining. 
Densitometric analysis of the bands was performed using a 
computerized densitometer. 
2.7. Assay of MMP-1, MMP-3, proMMP-9, and TIMP-1 
levels by Western blot analysis
  Cell supernatants were loaded on 8% polyacrylamide gels 
under denaturing and reducing conditions, with addition 
of Laemmli buffer, blotted on a polyvinylidene difluoride 
membrane, and probed with anti-human MMP-1, MMP-3, 
MMP-9, and TIMP-1 monoclonal Abs at 1/500-1 000
final dilution. Bands were visualized by enhanced 
chemiluminescence. Densitometric analysis of the bands 
was performed using a computerized densitometer. 
2.8. Statistical analysis
  All data were obtained from three independent experiments 
with similar results. Results are shown as a representative 
image (gelatin zymography and Western blot analysis) or as 
mean values 依 SD (densitometric analysis). All densitometric 
data were analyzed by Student’s t-test.
 
3. Results
3.1. P. falciparum-infected RBCs induce release of active 
MMP-9 but not of active MMP-2 protein from HMEC-1
  HMEC-1 were treated with RBCs infected by late stage 
trophozoites of two different strains of P. falciparum (D10, 
chloroquine-sensitive; and W2, chloroquine-resistant) 
for 72 h. Further investigation on cell supernatants was 
performed by SDS-PAGE gelatin zymography followed by 
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densitometric analysis to assess the levels of MMP-2/MMP-9 
precursors and activated forms. Since the assay is equally 
sensitive for the pro-enzymes (inactive in solution) and the 
active forms, and because TIMPs and other endogenous 
inhibitors are dissociated from the enzyme during the SDS-
electrophoresis, the intensity of the bands reflects the levels 
of the different forms of the gelatinases and not their net 
activities. 
  As shown in Figure 1, proMMP-9 and MMP-9 were absent 
in untreated HMEC-1 supernatants, whereas they were 
induced de novo by infected RBCs. Moreover, untreated 
control cells showed low levels of proMMP-2, which were 
not significantly altered by infected RBCs. The parasite 
effects on gelatinases production were not strain-specific, 
since no significant differences were found between the 
levels of gelatinases production after treatment with D10- 
or W2-infected erythrocytes. Moreover, when HMEC-1 
were co-incubated with infected RBCs for 3 h, washed and 
kept in culture for other 72 h, results were similar to those 
obtained with 72 h of co-incubation (data not shown). 
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Figure 1. Effects of trophozoite-stage P. falciparum-infected RBCs 
on gelatinase levels in HMEC-1 supernatants. 
A: representative gelatin zymogram from three different experiments, 
with 92 kDa, 83 kDa, and 72 kDa band representing proMMP-9, 
MMP-9, and proMMP-2 protein levels, respectively; B-D: 
densitometric analysis of gelatin zymography data, shown as means + 
SD. All densitometric data were analyzed for significance by Student’s 
t-test, with 3vs2: P not significant in all panels; 2/3vs1: P<0.001 in 
B-C and P not significant in D.
 
3.2. P. falciparum-infected RBCs impair the balance between 
pro-MMP-9 and TIMP-1 proteins released from HMEC-1
  HMEC-1 was treated with RBCs infected by late stage 
trophozoites of D10 and W2 strains of P. falciparum for 
72 h. Thereafter, cell supernatants were collected and 
protein levels of proMMP-9 and TIMP-1, the endogenous 
inhibitor of MMP-9, were analyzed by western blotting 
followed by densitometric quantification. As shown in 
Figure 2, proMMP-9 protein was absent in untreated 
HMEC-1 supernatants, whereas it was induced de novo 
by both parasite strains. On the contrary, the basal levels 
of TIMP-1 were not significantly altered by either parasite 
strain-infected RBCs.  The effects of P. falciparum-infected 
erythrocytes were not strain-dependent, since no significant 
differences between either parasite strain were found.
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Figure 2. Effects of trophozoite-stage P. falciparum-infected RBCs 
on proMMP-9 (A) and TIMP-1 (B) protein release from HMEC-1. 
Upper panels: representative western blots, with 92 kDa and 22 
kDa bands representing proMMP-9 and TIMP-1 protein levels, 
respectively; lower panels: mean densitometric values 依 SD. All 
densitometric data were analyzed for significance by Student’s t-test, 
with 3vs2: P not significant in all panels; 2/3vs1: P<0.001 in A and P 
not significant in B.
 
3.3. P. falciparum-infected RBCs enhance protein release of 
MMP-3 and MMP-1 from HMEC-1
  HMEC-1 was treated with RBCs infected by late stage 
trophozoites of D10 and W2 strains of P. falciparum for 72 h.
Thereafter, cell supernatants were collected and protein 
levels of MMP-3 and MMP-1, two enzymes sequentially 
involved in proMMP-9 proteolytic activation, were analyzed 
by western blotting followed by densitometric quantification. 
As shown in Figure 3, both protein levels of MMP-3 and 
MMP-1 released from HMEC-1 were significantly enhanced 
after stimulation with P. falciparum-infected erythrocytes. 
Parasite-dependent upregulation of MMP-3/MMP-1 
protein release was not strain-specific, and no significant 
differences were found whether D10- or W2-infected 
erythrocytes were used. 
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Figure 3. Effects of trophozoite-stage P. falciparum-infected RBCs 
on MMP-3 (A) and MMP-1 (B) protein release from HMEC-1. 
Upper panels: representative western blots, with 57 kDa and 52 kDa 
bands representing MMP-3 and MMP-1 protein levels, respectively; 
lower panels: mean densitometric values 依 SD. All densitometric data 
were analyzed for significance by Student’s t-test, with 3vs2: P not 
significant in both panels; 2/3vs1: P<0.001 in A and P<0.01 in B.
4. Discussion
  The complications of P. falciparum malaria, including 
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CM, are associated to cytoadherence of RBCs to activated 
endothelial cells overexpressing several adhesion molecules, 
such as intracellular adhesion molecule-1 and vascular 
cell adhesion molecule-1[24]. Therefore, microcirculatory 
obstruction, tissue hypoxia and metabolic disturbances 
occur as a result of infected RBCs sequestration in human 
microvessels[25]. Parasite-dependent endothelial activation 
is also associated with modulation of the production of 
proinflammatory cytokines, including TNFalpha, IL-6 and 
IL-8[26], and vasoactive mediators, like constitutive and 
inducible endothelin-1[27,28]. Moreover, parasitized RBCs 
were shown in vitro to decrease trans-endothelial electrical 
resistance and permeability of the blood-brain barrier (BBB)
[29], two features of CM which in vivo lead to brain oedema 
and ring haemorrhages[25]. Here we show that the treatment 
of a human microvascular cell line (HMEC-1) with RBCs 
infected by two different strains of P. falciparum (D10 and 
W2) modified the pattern and the levels of released MMPs 
and TIMPs. The percentages of parasitemia (5%-10%) used 
in these experiments are relevant to biological conditions 
associated with severe malaria. Hyperparasitaemia in 
falciparum malaria is defined as >4% parasitized RBCs in 
the peripheral blood, although locally in the small vessels of 
the brain it may be much higher due to sequestration[30]. 
  A first screening by gelatin zymography measuring the 
levels of precursors and active forms of gelatinases revealed 
de novo induction by parasitized RBCs of either pro- 
or active MMP-9 protein release, without altering basal 
levels of proMMP-2 and without promoting any proMMP-2 
activation. This evidence is consistent with previous data 
showing MMP-9 induction in human endothelial cells 
isolated from large calibre vessels after treatment with RBCs 
infected by P. falciparum trophozoites[3]. Moreover it was 
previously shown that in human monocytes, phagocytosis 
of trophozoite-stage parasitized RBCs, enhances the 
basal levels of constitutively secreted MMP-9[13,16]. 
Interestingly, trophozoites contain high amounts of HZ, a 
ferriprotoporphyrin 桖 crystal bound to a large spectrum 
of proteins and lipids of host or parasite origin, which has 
been directly related to MMP-9 overexpression[3,13-17,21] and 
activation[31].
  The endogenous inhibitor of MMP-9 is TIMP-1, which 
acts by chelating the zinc of the metalloproteinase active 
site, thereby contrasting any effects of the MMP pro-
peptide removal and blocking the enzymatic activity[32]. In 
previous studies, parasitized RBCs did not alter TIMP-1 
mRNA in human brain microvascular endothelial cells[26], 
whereas HZ did not modify TIMP-1 protein levels secreted 
by human dermal microvascular endothelium[21]. This 
evidence is consistent with results from the present study, 
which did not highlight any modification of basal TIMP-1 
protein levels released from HMEC-1 after treatment with 
parasitized RBCs. Thus, the parasite-mediated induction of 
MMP-9 might be the net effect of increased proMMP-9 and 
unaltered TIMP-1 release.
  Furthermore, mechanisms underlying proMMP-9 activation 
require a proteolytic cascade sequentially involving 
plasminogen, MMP-3 and MMP-1[33]. In the present work, 
both basal MMP-3 and MMP-1 proteins were enhanced 
by parasitized RBCs; these increases might explain the 
parasite-induced levels of active MMP-9 previously 
described. A similar modulation of MMPs and their inhibitors 
has been demonstrated in the same cell line treated with 
HZ[21]; additionally, accumulation of MMP-1 and urokinase-
type plasminogen activator receptor has been described in 
the brains of patients with fatal CM[8,34], suggesting that the 
proMMP-9 proteolytic machinery is activated in areas of 
intense parasite sequestration and vascular damage. 
  Nevertheless, a crucial point highlighted by this work 
is that the observed effects on endothelial MMP/TIMP 
regulation was promoted by both D10 and W2 parasite 
strains in a similar way, suggesting that modulation of MMP/
TIMP production by endothelial cells is independent on 
parasite phenotype. This evidence makes MMPs potential 
targets for an adjunctive therapy since MMPs, as a result of 
their proteolytic activity, play a broad spectrum of effects 
directly connected to CM features. Indeed, it has been 
shown that several MMPs, including MMP-9, are able to 
process inter-endothelial tight junctions proteins, such as 
cerebral occludin and claudin-5[35] or the BBB protein beta-
dystroglycan[36], and cleavage of these proteins could cause 
increased BBB permeability. Moreover, MMPs also modulate 
the activity of several pro-inflammatory molecules, such as 
TNFalpha, IL-1beta, IL-8 and ENA-78[7], thus amplifying 
the local inflammatory response.
  In conclusion, the present study shows that P. falciparum 
parasites, either chloroquine-sensitive or -resistant, 
promote the release of active MMP-9 protein from human 
microvascular endothelial cells, as a result of impaired 
balance between proMMP-9 and its inhibitor TIMP-1, and 
of enhanced levels of its activators MMP-3 and MMP-1. 
This work provides new evidence on MMP involvement in 
malaria, and might help to better understand mechanisms 
of complicated malaria. Moreover, it strengthens previous 
evidence pointing at MMPs - MMP-9 in particular - as 
possible targets for new adjunctive therapies against 
falciparum malaria, aimed to prevent lethality associated 
with the severe form of the disease. 
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